Tag Archives: Kedrion Biopharma

November, 2016

7 November
FDA Accepts Kedrion and Kamada’s BLA for Human Rabies Immunoglobulin

FORT LEE, N.J. & NESS ZIONA, Israel–(BUSINESS WIRE)–Kedrion Biopharma, and Kamada Ltd. (NASDAQ and TASE:KMDA), two leading human-derived protein therapeutics companies, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for a human anti-rabies immunoglobulin (IgG) therapy. Rabies is a …
Share

28 March
Kedrion Biopharma Receives FDA Approval to Package Koāte® Double Viral Inactivation (DVI) Antihemophilic Factor (human) with Mix2VialTM Needle-Free Transfer Device

FORT LEE, N.J.–(BUSINESS WIRE)–Kedrion Biopharma: Kedrion Biopharma will extend its focus on patients by offering Mix2Vial™, a needle-free, double-ended, all plastic filter transfer set for use in reconstituting Koāte® Double Viral Inactivation (DVI) Antihemophilic Factor (human), a lyophilized (i.e., powdered) human factor-derived clotting factor Mix2Vial reduces exposure to accidental needle …
Share

20 January
Kedrion Biopharma Expands Immunoglobulin Therapies Portfolio, Gains Commercial Rights in the U.S. to BIVIGAM®, a Recently Approved IGIV Brand

Kedrion Biopharma Inc., established in the U.S. market in 2011, is an emerging player in the rare disease arena The Company aims to build business rapidly through ongoing organic growth of its brand portfolio and strategic partnerships with other industry leaders Gaining rights to commercialize BIVIGAM® [Immune Globulin Intravenous (Human), …
Share